Advertisement
BioFinance 2008 is the Canadian Life Science industry's leading investorconference. The meeting brings together key industry players to considerinvestment opportunities and issues affecting companies in biotechnology,medical devices, diagnostics and research tools. Participants include seniorlife science executives, institutional and venture capital investors, industryanalysts, corporate finance executives and experts from the scientific andmedical communities in Canada, the United States, Europe and Asia.
Advertisement
About Haemacure
Haemacure Corporation is a specialty biotherapeutics company developinghigh-value human plasma-derived protein products for commercialization.Haemacure's research and development effort is driven by its proprietaryplasma protein extraction technology to develop next-generation products,including surgical hemostats. Haemacure's lead product candidate,Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/PhaseIII clinical trials during the first quarter of 2009. Haemacure's secondproduct candidate is thrombin, a component of its fibrin sealant, now inpreclinical stage. Follow-on development will focus on surgical hemostats,wound healing, adhesion prevention, regenerative medecine, drug delivery andcombination with biomaterials. Haemacure has discovered eleven additionalspecialty proteins and enzymes in one if its two plasma fractions and seeks toadvance these proteins and enzymes through partnerships with pharmaceuticaland biotechnology companies. Haemacure operates offices in Sarasota, Floridathrough a wholly-owned subsidiary. The Corporation is traded under stocksymbol HAE on the TSX.
Forward-looking Statements
Certain of the statements contained in this news release areforward-looking statements. Such statements, based as they are on the currentexpectations of management, inherently involve numerous risks anduncertainties, known and unknown. Some examples of known risks are: the impactof general economic conditions, general conditions in the biotech industry,changes in the regulatory environment in the jurisdictions in which Haemacuredoes business, stock market volatility, fluctuations in costs, and changes tothe competitive environment due to consolidation or otherwise. Consequently,actual future results may differ materially from the anticipated resultsexpressed in the forward-looking statements. Haemacure disclaims any intentionor obligation to update these statements.
SOURCE HAEMACURE CORPORATION